Pharmacokinetic evaluation of fosaprepitant dimeglumine

Bibliography

• Kris MG, Hesketh PJ, Somerfield MR, American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol 2006;24(18):2932-47
   PubMed Web of Science ®Google Scholar
• Curran MP, Robinson DM. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009;69(13):1853-78
   PubMed Web of Science ®Google Scholar
• Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12(9):1143-50
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.2.2010; 2010. Available from: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf [Cited 10 July 2010]
   Google Scholar
• Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17(1):20-8
   PubMed Web of Science ®Google Scholar
• Le TP, Gan TJ. Update on the management of postoperative nausea and vomiting and postdischarge nausea and vomiting in ambulatory surgery. Anesthesiol Clin 2010;28(2):225-49
   PubMedGoogle Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97(12):3090-8
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Emend (fosaprepitant dimeglumine) for injection. White House Station, NJ, USA; 2008
   Google Scholar
• Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother 2005;19(3):31-9
   PubMedGoogle Scholar
• Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002;63(Suppl 11):18-24
   PubMedGoogle Scholar
• Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250(1):R5-6
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21(22):4112-19
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Herrstedt J, Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006;14(4):354-60
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S, Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17(6):1000-6
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23(12):2822-30
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):v232-43
   PubMed Web of Science ®Google Scholar
• BC Cancer Agency – SCNAUSEA Protocol: British Columbia Cancer Agency; 2009
   Google Scholar
• EMEA. Questions and answers on the withdrawal of the marketing authorisation application for Zunrisa: casopitant; 2009
   Google Scholar
• GSK. Regulatory update for REZONICTM (casopitant mesylate); 2009
   Google Scholar
• ClinicalTrials.gov; 2010. Available from: http://clinicaltrials.gov/ct2/results?term=casopitant [Cited 29 May 2010]
   Google Scholar
• Hale JJ, Mills SG, MacCoss M, Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 2000;43(6):1234-41
   PubMed Web of Science ®Google Scholar
• Huskey S-EW, Luffer-Atlas D, Dean BJ, Substance P receptor antagonist I: conversion of phosphoramidate prodrug after i.v. Administration to rats and dogs. Drug Metab Dispos 1999;27(11):1367-73
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Gambale J, Jin B, Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007;47(7):834-40
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Howard L, Goldberg MR, Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46(3):291-300
   PubMed Web of Science ®Google Scholar
• Depre M, Van Hecken A, Oeyen M, Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61(5-6):341-6
   PubMed Web of Science ®Google Scholar
• Cocquyt V, Van Belle S, Reinhardt RR, Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001;37(7):835-42
   PubMed Web of Science ®Google Scholar
• Simon VB, Michael RL, Rudolph MN, Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94(11):3032-41
   PubMed Web of Science ®Google Scholar
• FDA. Code of Federal Regulations Title 21; 2009: 21CFR320.1
   Google Scholar
• Grunberg SM, Chua DT, Maru A, Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 2010;28:15s (Suppl; abstr 9021)
   PubMedGoogle Scholar
• ClinicalTrials.gov; 2010. Available from: http://clinicaltrials.gov/ct2/results?term=fosaprepitant [Cited 18 April 2010]
   Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59(7):631-44
   PubMed Web of Science ®Google Scholar
• Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008;3(3):295-309
   PubMed Web of Science ®Google Scholar
• Marbury TC, Jin B, Panebianco D, Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesth Analg 2009;109(2):418-25
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 2009;20(Suppl 4):iv156-8
   Google Scholar
• Munoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 2010;28(2):187-93
   PubMed Web of Science ®Google Scholar
• Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10(1):23-31
   PubMed Web of Science ®Google Scholar